CoChat

Proceedings of the Australian Neuroscience Society Symposium: Schizophrenia MOLECULAR GENETICS OF SCHIZOPHRENIA

Mowry, Bj, Nancarrow, Dj · 2001 · Clinical and Experimental Pharmacology and Physiology
Cited by 88

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

SUMMARY: 1. Schizophrenia is a chronic, disabling brain disease that affects approximately 1% of the world’s population. It is characterized by delusions, hallucinations and formal thought disorder, together with a decline in socio‐occupational functioning. While the causes for schizophrenia remain unknown, evidence from family, twin and adoption studies clearly demonstrates that it aggregates in families, with this clustering largely attributable to genetic rather than cultural or environmental factors. Identifying the genes involved, however, has proven to be a difficult task because schizophrenia is a complex trait characterized by an imprecise phenotype, the existence of phenocopies and the presence of low disease penetrance. 2. The current working hypothesis for schizophrenia causation is that multiple genes of small to moderate effect confer compounding risk through interactions with each other and with non‐genetic risk factors. The same genes may be commonly involved in conferring risk across populations or they may vary in number and strength between different populations. To search for evidence of such genetic loci, both candidate gene and genome‐wide linkage studies have been used in clinical cohorts collected from a variety of populations. Collectively, these works provide some evidence for the involvement of a number of specific genes (e.g. the 5‐hydroxytryptamine (5‐HT) type 2a receptor (5‐HT 2a) gene and the dopamine D 3 receptor gene) and as yet unidentified factors localized to specific chromosomal regions, including 6p, 6q, 8p, 13q and 22q. These data provide suggestive, but no conclusive, evidence for causative genes. 3. To enable further progress there is a need to: (i) collect fine‐grained clinical datasets while searching the schizophrenia phenotype for subgroups or dimensions that may provide a more direct route to causative genes; and (ii) integrate recent refinements in molecular genetic technology, including modern composite marker maps, DNA expression assays and relevant animal models, while using the latest analytical techniques to extract maximum information in order to help distinguish a true result from a false‐positive finding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1440-1681.2001.03399.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 88

Metadata

Authors
Mowry, B., & Nancarrow, D.
Venue
Clinical and Experimental Pharmacology and Physiology
Publisher
Wiley
Published
2001-01
Volume
28
Issue
1-2
Pages
66-69
ISSN
  • 0305-1870 (ISSN-L)
  • 1440-1681
OpenAlex
W2069169238
Cited by
88
References
3
FWCI
4.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proceedings of the Australian Neuroscience Society Symposium: Schizophrenia MOLECULAR GENETICS OF SCHIZOPHRENIA. https://app.cochat.ai/papers/10.1046/j.1440-1681.2001.03399.x
The paper
Mowry, B., & Nancarrow, D. (2001). Proceedings of the Australian Neuroscience Society Symposium: Schizophrenia MOLECULAR GENETICS OF SCHIZOPHRENIA. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1046/j.1440-1681.2001.03399.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.